ArticleBMC infectious diseases2026
Characterization of the activation status of T lymphocyte subpopulations in peripheral blood from localized and diffused cutaneous leishmaniasis patients at the University of Gondar Hospital, Ethiopia.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundCutaneous leishmaniasis (CL) is the most common clinical form of leishmaniasis and remains a major public health problem worldwide. In the Ethiopian setting, reports regarding the human immune response against CL infection are limited. Therefore, this study aimed to determine T lymphocyte subpopulations’ frequency, activation, and proliferation status from peripheral blood of LCL and DCL patients at the University of Gondar Hospital.
methodsAn institutional based cross-sectional study was conducted on 22 confirmed CL patients attending the Leishmania Research and Treatment Center (LRTC) of the University of Gondar Hospital from January to June 2017. As a control, 14 healthy participants were recruited from Voluntary Counseling and Testing (VCT) clinics of selected health centers. Blood samples were stained, and surface marker expression was evaluated by flow cytometry. Statistical analysis was performed using Kruskal-Wallis followed by Dunn’s multiple comparisons test and the differences were considered statistically significant when the P-values were < 0.05. In this study, all the results are expressed as medians with inter-quartile range (IQR).
resultsBoth DCL and LCL subjects showed an increased expression of CD38 and HLA-DR markers on T cell subsets compared to control groups. A significant reduction in the frequency of CD8+ T cells was observed in the DCL as compared to the LCL patients (P = 0.04). The co-expression of CD38 and HLA-DR markers on CD4+ and CD8+ T cells was significantly higher among DCL patients when compared with health controls (HC) (P = 0.04) and (P = 0.01), respectively. In contrast, the proliferation marker Ki-67 expression by activated cells did not show significant differences between the CL cases and HC (p > 0.05).
conclusionThe expression levels of activation markers are associated with the LCL and DCL clinical forms of L. aethiopica caused CL. The presence of elevated levels of activated non-proliferating immune cells in DCL cases, as well as reduced numbers of CD8 T cells is consistent with a mechanism of T-cell activation followed by anergy and/or apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.